GERN

Company Overview — What Does GERON CORP Do?

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California. GERON CORP (GERN) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO John A. Scarlett and employs approximately 70 people, headquartered in MENLO PARK, California. With a market capitalization of $1.1B, GERN is one of the notable companies in the Healthcare sector.

GERON CORP (GERN) Stock Rating — Reduce (April 2026)

As of April 2026, GERON CORP receives a Reduce rating with a composite score of 32.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.GERN ranks #2,067 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, GERON CORP ranks #229 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

GERN Stock Price and 52-Week Range

GERON CORP (GERN) currently trades at $1.69. The stock lost $0.07 (4.0%) in the most recent trading session. The 52-week high for GERN is $2.01, which means the stock is currently trading -15.9% from its annual peak. The 52-week low is $1.04, putting the stock 62.5% above its annual trough. Recent trading volume was 16.6M shares, indicating strong institutional interest and high liquidity.

Is GERN Overvalued or Undervalued? — Valuation Analysis

GERON CORP (GERN) carries a value factor score of 26/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 4.93x, versus the sector average of 2.75x. The price-to-sales ratio is 6.79x, compared to 1.66x for the average Healthcare stock.

At current multiples, GERON CORP trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

GERON CORP Profitability — ROE, Margins, and Quality Score

GERON CORP (GERN) earns a quality factor score of 20/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -35.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -14.2% versus the sector average of -33.1%.

On a margin basis, GERON CORP reports gross margins of 98.0%, compared to 71.5% for the sector. The operating margin is -49.2% (sector: -66.1%). Net profit margin stands at -54.0%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 5254.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

GERN Debt, Balance Sheet, and Financial Health

GERON CORP has a debt-to-equity ratio of 153.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 4.66x, indicating strong short-term liquidity. Total debt on the balance sheet is $119M. Cash and equivalents stand at $78M.

GERN has a beta of 1.32, meaning it is more volatile than the broader market — a $10,000 investment in GERN would be expected to move 32.4% more than the S&P 500 on any given day. The stability factor score for GERON CORP is 34/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

GERON CORP Revenue and Earnings History — Quarterly Trend

In TTM 2026, GERON CORP reported revenue of $164M and earnings per share (EPS) of $-0.13. Net income for the quarter was $-81M. Gross margin was 98.0%. Operating income came in at $-71M.

In FY 2025, GERON CORP reported revenue of $184M and earnings per share (EPS) of $-0.13. Net income for the quarter was $-84M. Revenue grew 138.8% year-over-year compared to FY 2024. Operating income came in at $-69M.

In Q3 2025, GERON CORP reported revenue of $47M and earnings per share (EPS) of $-0.03. Net income for the quarter was $-18M. Revenue grew 67.1% year-over-year compared to Q3 2024. Operating income came in at $-14M.

In Q2 2025, GERON CORP reported revenue of $49M and earnings per share (EPS) of $-0.02. Net income for the quarter was $-16M. Revenue grew 5459.6% year-over-year compared to Q2 2024. Operating income came in at $-12M.

Over the past 8 quarters, GERON CORP has demonstrated a growth trajectory, with revenue expanding from $882,000 to $164M. Investors analyzing GERN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

GERN Dividend Yield and Income Analysis

GERON CORP (GERN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

GERN Momentum and Technical Analysis Profile

GERON CORP (GERN) has a momentum factor score of 47/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 20/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 51/100 reflects moderate short selling activity.

GERN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, GERON CORP (GERN) ranks #229 out of 838 stocks based on the Blank Capital composite score. This places GERN in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing GERN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full GERN vs S&P 500 (SPY) comparison to assess how GERON CORP stacks up against the broader market across all factor dimensions.

GERN Next Earnings Date

No upcoming earnings date has been announced for GERON CORP (GERN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy GERN? — Investment Thesis Summary

The quantitative profile for GERON CORP suggests caution. The quality score of 20/100 flags below-average profitability. The value score of 26/100 indicates premium valuation. High volatility (stability score 34/100) increases portfolio risk.

In summary, GERON CORP (GERN) earns a Reduce rating with a composite score of 32.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on GERN stock.

Related Resources for GERN Investors

Explore more research and tools: GERN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare GERN head-to-head with peers: GERN vs AZN, GERN vs SLGL, GERN vs VMD.